Loading provider…
Loading provider…
Hematology & Oncology Physician in Louisville, KY
NPI: 1144209982Primary Practice Location
UNIVERSITY OF LOUISVILLE HOSPITAL
530 S Jackson St, Louisville, KY
Primary Employer
Ulrf Oncology
uoflhealth.org
HQ Phone
Get MD Vivek's Phone NumberMobile
Get MD Vivek's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardKY State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 152 | 501 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 22 | 41 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 22 | 22 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 14 |
| 5 | 99221Initial hospital inpatient care, typically 30 minutes per day | 12 | 14 |
Antiplatelet Agents in Sepsis-Putting it all together: A Call to Action.
Authors: Tiwari, Nishant R, Chaudhari, Kaustubh S, Sharma, Richa, Haas, Kevin P, Sharma, Vivek R
Journal: Indian J Crit Care Med
COVID-19 and thrombotic microangiopathies.
Authors: Tiwari, Nishant R, Phatak, Sanat, Sharma, Vivek R, Agarwal, Sanjay K
Journal: Thromb Res
Publication Date: 2021-04-20
Lead Sponsor: University of Louisville
Collaborators: James Graham Brown Cancer Center
Intervention / Treatment: RADIATION: Stereotactic Body Radiation Therapy, DRUG: Folfirinox
Lead Sponsor: Hutchison Medipharma Limited
Intervention / Treatment: DRUG: Placebo, DRUG: Fruquintinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Sunitinib Malate, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Osimertinib, PROCEDURE: Biospecimen Collection, DRUG: Dabrafenib, DRUG: Crizotinib, DRUG: Sapanisertib, DRUG: Taselisib, PROCEDURE: Computed Tomography, BIOLOGICAL: Trastuzumab, DRUG: Trametinib, PROCEDURE: Multigated Acquisition Scan, DRUG: Palbociclib, DRUG: Afatinib, DRUG: Ulixertinib, OTHER: Cytology Specimen Collection Procedure, DRUG: Dasatinib, DRUG: Vismodegib, DRUG: Afatinib Dimaleate, DRUG: Adavosertib, PROCEDURE: Biopsy Procedure, DRUG: Defactinib, PROCEDURE: Radionuclide Imaging, BIOLOGICAL: Trastuzumab Emtansine, DRUG: Copanlisib, PROCEDURE: Echocardiography Test, DRUG: PI3K-beta Inhibitor GSK2636771, DRUG: Larotrectinib, BIOLOGICAL: Relatlimab, DRUG: Copanlisib Hydrochloride, DRUG: Capivasertib, DRUG: Erdafitinib, DRUG: Larotrectinib Sulfate, DRUG: Binimetinib, BIOLOGICAL: Pertuzumab, DRUG: Ipatasertib, DRUG: Dabrafenib Mesylate, DRUG: Defactinib Hydrochloride, DRUG: Fexagratinib, PROCEDURE: Radiologic Examination